# Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

> **NCT02899156** · PHASE4 · TERMINATED · sponsor: **University of California, Davis** · enrollment: 22 (actual)

## Conditions studied

- Hypoactive Delirium

## Interventions

- **DRUG:** Flumazenil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02899156
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-04-16
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899156, "Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02899156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*